Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3962MR)

This product GTTS-WQ3962MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3962MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11882MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ197MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ4070MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ3361MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ7671MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ9060MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ8474MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ13794MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10933
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW